{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003368","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.918492+00:00","generated_at":"2026-06-26T23:57:42.877231+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances","bullets":["Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.","Full year 2021 revenue $29.6M (vs $7.9M in 2020); net income $376K ($0.01/sh) vs net loss $18.2M in 2020.","Cash $30.4M at Dec 31, 2021 plus $10M collected in Q1 2022; expects to fund operations into Q2 2023.","CLS-AX OASIS Phase 1/2a: Cohort 3 results expected mid-2022; new Cohort 4 planned Q2 2022 to explore higher doses.","XIPERE launched by Bausch + Lomb in U.S. in Q1 2022 for uveitic macular edema after FDA approval Oct 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003368","json":"https://secwatch.observer/filing/0000950170-22-003368.json","markdown":"https://secwatch.observer/filing/0000950170-22-003368.md","text":"https://secwatch.observer/filing/0000950170-22-003368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/0000950170-22-003368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/clsd-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:57:42.877231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}